Jul 31, 2021 15:09 UTC

London-based Advanz Pharma and its subsidiaries were found to have charged “excessive and unfair prices” between 2009 and 2017 for liothyronine tablets, primarily used to treat hypothyroidism, which affects at least two in every 100 people and can lead to depression, tiredness and weight gain.